בתוך הירידות: 4 מניות מומלצות של בנק לאומי בחו"ל

תודה רבה לשמוליק קרפף!

המעניין שיורד גשם הוא יורד על כולם תודה לך

SPHS the risk/reward ratio is very impressive considering current cap($27m),other P3 companies and the competitor market value.if thinks go right in 2016(and i believe they will),$100m-$200m (or $6-$12 PPS) will be very reasonable market cap,imo "Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.” The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added. Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects." Also mentioned: "Our due diligence suggests that Sophiris has more than en